The aim of this analysis was to examine the influence of different in-cath-lab antiplatelet regimens for the primary percutaneous coronary intervention (PCI) on all-cause mortality.
Introduction
Several meta-analyses have demonstrated an improved survival with inhibition of platelet glycoprotein (GP) IIb/IIIa receptors during primary percutaneous coronary intervention (PCI) in up to 12 months follow-up. 1, 2 Much less is known about clopidogrel in the setting of primary PCI. Only one sub-analysis of patients treated primarily with fibrinolysis and subsequently with angioplasty proved that clopidogrel pretreatment reduced ischaemic complications before and after PCI. 3 Also only one large-scale registry confirmed that adjunctive therapy with clopidogrel is associated with a reduction of 1 year mortality after reperfusion therapy (primary PCI or fibrinolysis). 4 There is almost no data on mortality reduction of GP IIb/IIIa inhibitors added to loading doses of clopidogrel and aspirin, which emerged as standard adjunctive antiplatelet therapy in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary PCI. 5 -7 Moreover, there are concerns that aggressive antiplatelet regimens may increase bleeding complications and adverse outcomes. 8 Because primary PCI is proved to be a preferred approach in patients with STEMI, it is essential to establish the efficacy of this triple antiplatelet therapy. The aim of this analysis was to examine the influence of different antiplatelet regimens for the primary PCI on all-cause mortality.
Methods

Patient population
The registry enrolled all patients who underwent PCI (92% primary, 7% facilitated or rescue) because of the first or recurrent STEMI, in 38 cardiac catheterization laboratories (cath-labs) throughout Poland. Patients were recruited into the registry between 1 January 2003 and 31 December 2003. All demographic, clinical, and angiographic data, including variations of pharmacological and interventional treatment as well as complications were prospectively collected in the Data Base of the Working Group on Cardiovascular Interventions of the Polish Cardiac Society (DB-PCS), which registers the invasive percutaneous procedures performed in Polish catheterization laboratories from 2002. In each hospital, necessary data were collected using supplied software on dedicated computers and sent to DB-PCS via internet once a month. Initial editing and checking for missing data were implemented by software. Patients were followed for minimum 1 year to over 2 years and mortality data were derived from General Electronic Population Death Registry System of the Ministry of Internal Affairs and Administration of Poland. The study was approved by the Ethics Committee of Institute of Cardiology in Warsaw. In 2003 in Poland 27 489 PCIs were performed for emergency indications (17 211 because of myocardial infarction and 10 278 owing to unstable angina). Only 14 881 (54%) procedures were entered into DB-PCS, because not all cath-labs participated in the registry at that time. Of those, 13 457 (90%) had complete data and were subsequently evaluated. In this group initial diagnosis of STEMI was put in 7353 individuals. The first primary PCI procedure in each case during study period was further analysed, giving a total of 7193 procedures.
Definitions and study endpoint STEMI was diagnosed in the presence of the two following criteria: persistent anginal pain for 20 min and ST-segment elevation of .1 mm in two or more standard leads or 2 mm in two or more contiguous precordial leads or the presence of new left bundle branch blocks. 9 Shock at admission was defined with the means of Killip-Kimball score. Culprit lesion was defined as thrombus containing stenosis or acute vessel closure located in a coronary vessel supplying area of myocardium corresponding to ST-segment elevation in . The selection of the variables was based on expert choice of clinically important ones. The C-statistics for the models ranged from 0.654 to 0.747 and propensity score ranges were overlapping (allowing for group-matching). For each comparison group propensity scores were used to create a one-to-one matched sample using group with smaller number of cases as a baseline, the sampling was performed without replacement and calliper was set to 0.25 standard deviations of estimated propensity score. The tests of matched-samples have shown good balance in control variables (i.e. sex, age, history of previous MI, hyperlipidaemia, diabetes mellitus, shock at admission, history of renal failure, PCI delay, number of diseased vessels, TIMI flow before and after PCI, primary or facilitated or rescue PCI, direct or elective stenting or balloon angioplasty, number of dilated vessels, number of stents implanted, no-reflow phenomenon). 11 A comparison of time-to-death between patients who received clopidogrel, GP IIb/IIIa inhibitors, both medications, or none was performed using Kaplan-Meier method. Log-rank test was employed to check for statistical difference between survival curves in propensity scorematched samples. Because there is an ongoing dispute in the literature on whether the tests performed should use pairing assumption, we report the results of unpaired and paired tests. 12 The conclusions are the same in both cases. Because four tests were performed, Bonferroni method was applied to control for multiple testing, but it did not influence the results. In all tests P-value of 0.05 was considered significant with two-sided alternative hypothesis assumption. Statistical analyses were performed using R 2.8 statistical package. 13 [Detailed information on the results of statistical analysis (like tests of balance for matched samples) are omitted in the paper and are available upon request.]
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Results
Baseline characteristics
All patients received pretreatment with 300 mg of aspirin followed by 75 mg daily, 992 (14%) pts received in-cath-lab GP IIb/IIIa inhibitors, 2690 pts (37%) were treated in cath-lab with 300 mg loading dose of clopidogrel followed by 75 daily and 1566 (22%) received combined in-cath-lab antiplatelet treatment with both GP IIb/IIIa inhibitors and clopidogrel. Remaining 1945 patients (27%) did not receive GP IIb/IIIa inhibitors or clopidogrel. Baseline clinical and angiographic characteristics according to antiplatelet treatment strategy is presented in Table 1 . Early and late outcomes in relation to study group are shown in Table 2 . Because of between-group differences in the baseline characteristics, all of the analysed parameters were included in the propensity score calculation. It also included two early outcome measures, no-reflow and TIMI flow post-PCI, as they could have potentially influenced the administration of GP IIb/IIIa inhibitors.
Survival analysis
Both unadjusted Kaplan -Meier curves and propensity-adjusted survival analysis disclosed no additive effect on survival of a combination therapy with GP IIb/IIIa inhibitors and clopidogrel in comparison to treatment with clopidogrel alone (Figures 1 and 2A , respectively). The same analyses showed significant benefit of combination therapy with GP IIb/IIIa inhibitors and clopidogrel, clopidogrel alone, and GP IIb/IIIa inhibitors alone over aspirin only ( Figure 2B -D, respectively).
Discussion
In a presented large cohort, multicentre, observational registry both clopidogrel and GP IIb/IIIa inhibitors (abciximab in 76% of patients) administered in cath-lab independently reduced all-cause mortality in patients treated with primary PCI. Adjunctive intravenous administration of GP IIb/IIIa inhibitors on top of 300 mg loading dose of clopidogrel did not further improve the outcome in comparison to monotherapy with either clopidogrel or GP IIb/IIIa inhibitors. Our results concerning the benefits of GP IIb/IIIa inhibitors used alone are concordant with previously published meta-analyses of the randomized clinical trials demonstrating significant reduction of mortality up to 12 months follow-up post-STEMI.
1,2 However, clinical trials included in those meta-analyses were performed before the introduction of antiplatelet treatment recommendations for STEMI used in 2003. 14 In most of those studies baseline antiplatelet therapy consisted of ticlopidine treatment 250 mg twice daily or clopidogrel 75 mg daily without a loading dose. 15 -21 It was subsequently proven that blood concentration of the active form of the aforementioned drugs reaches steady state only after few days of treatment and that loading dose of clopidogrel leads to faster onset of action and improves prognosis. 22 Before that era most patients had inadequate platelet inhibition in the first days after the procedure, which might have worsened the prognosis. The use of GP IIb/IIIa inhibitors before or during PCI was filling the time gap between the initiation of therapy with thienopyridines and acquisition of adequate platelet inhibition.
The demonstration that addition of GP IIb/IIIa inhibitors to loading doses of clopidogrel does not further reduce all-cause mortality after adjustment for potentially confounding factors may be clinically important as aggressive antiplatelet therapy has been shown to increase the incidence of bleeding. 8 Previous randomized study in patients undergoing PCI for stable or unstable angina without marked ST-segment shifts or positive biomarkers (low-to-intermediate risk profile) demonstrated that the use of abciximab offered no additional benefit in terms of mortality reduction at 1-year after pretreatment with 600 mg of clopidogrel. 23 Authors concluded that the spectrum of antithrombotic and anti-inflammatory effects ascribed to aspirin and clopidogrel may be sufficient to achieve effective platelet inhibition. It has been subsequently postulated that greater benefit from abciximab may be observed among patients with acute coronary syndromes, especially with elevated troponin levels (high-risk profile). 24 This subset of patients is characterized by an increased platelet activation and aggregation. However, a randomized study on high-risk patients with non-ST-segment elevation myocardial infarction (non-STEMI) undergoing PCI disclosed no additional mortality reduction at 1 year with abciximab after pretreatment with 600 mg of clopidogrel. 25 Our non-randomized analysis demonstrates that another high-risk group of patients with STEMI undergoing primary PCI does not benefit from GP IIb/IIIa inhibitors used on top of clopidogrel in terms of all-cause mortality reduction.
Our results correspond well with the Bavarian Reperfusion Alternatives Evaluation-3 (BRAVE) trial. 5 BRAVE-3 randomized patients with STEMI undergoing PCI within 24 h from the onset of pain to receive either abciximab or placebo in cath-lab in addition to 600 mg loading dose of clopidogrel and 500 mg loading dose of aspirin. The primary endpoint of infarct size measured with means of SPECT at 5 -7 days post-randomization was similar in both study groups. There was also no difference (although unpowered) in relation to single or combined secondary endpoints of 30-day mortality, stroke, non-fatal myocardial infarction, or urgent target vessel revascularization between two treatment strategies. At the same time abciximab infusion more frequently caused thrombocytopaenia and tended to increase minor bleeding events. Authors of the study concluded that in patients with acute STEMI treated with primary PCI who received pretreatment with high loading dose of clopidogrel, addition of abciximab does not reduce the infarct size. BRAVE-3 investigators used high loading dose of clopidogrel followed by 3 days of administration of 150 mg of clopidogrel and 75 mg daily thereafter. We demonstrate that GP IIb/IIIa inhibitors (mostly abciximab) added to even lower loading dose of clopidogrel (300 mg) and standard 75 mg/day maintenance dose also do not reduce mortality. Importantly, in contrast to BRAVE-3 trial presented group of patients was more representative of STEMI population, because it did not exclude patients with severe clinical state (such as cardiogenic shock) and had a high power to assess mortality. It can be speculated that timing of GP IIb/IIIa inhibitors administration can potentially influence the efficacy of treatment. Although not powered to assess mortality outcomes, recently published On-TIME 2 trial comparing early, pre-hospital administration of tirofiban vs. placebo in addition to 600 mg of clopidogrel and 500 mg of aspirin showed no improvement of 30-day survival. 6 In our study abciximab was administered intravenously. Recent communications suggest that intracoronary abciximab bolus resulting in high local drug concentrations may be more effective than standard intravenous treatment with respect to infarct size, extent of microvascular obstruction, and perfusion. 26 It is therefore possible that this new drug administration strategy would lead to different results, but there are no studies that assess mortality outcomes. In contrast to primary fibrinolysis the role of clopidogrel is less well-established in the setting of primary PCI. Our study is probably the first one to demonstrate that pretreatment with 300 mg therapy up to 4 weeks in patients with STEMI treated with fibrinolysis or without early reperfusion therapy. The only registry analysing the influence of clopidogrel on outcomes after primary PCI focused on STEMI survivors who were discharged with aspirin plus clopidogrel or aspirin alone. 4 However, the study did not report on clopidogrel pretreatment strategy or frequency. Our study has several limitations. First of all, it is not a randomized, controlled trial evaluating different antiplatelet treatment regimens in STEMI. The administration of clopidogrel or GP IIb/IIIa inhibitors was left to the discretion of the physician. This could result in selection bias, which cannot be fully eliminated by a multivariable analysis including adjustment by propensity score. For the purpose of the current analysis we decided to analyse different GP IIb/IIIa inhibitors used together for all indications including bail-out therapy, which could have to some extent influence the results. Although abciximab has more established position in the setting of primary PCI, then small molecule GP IIb/IIIa inhibitors recent trials demonstrate no significant differences in terms of outcomes between abciximab and tirofiban 28, 29 and between abciximab and eptifibatide. 30 Moreover, abciximab was used in 76% of cases of GP IIb/IIIa administration in our study and limitation of the GP IIb/IIIa group only to abciximab did not change the results (data not shown). At last, as presented dataset was an in-cath-lab registry we were unable to include data on some factors known to influence post-MI survival, such as pharmacological treatment both in hospital and at long-term regarding clopidogrel, statins, b-blockers, Figure 2 Survival analysis (Kaplan -Meier curves and log-rank P-values) for propensity-matched treatment groups.
angiotensin-converting enzyme-inhibitors, as well as the use of cardioverter-defibrillators or quantitative measure of infarct size and renal function.
Conclusions
In this non-randomized, large-cohort, multicentre STEMI registry in-cath-lab use of GP IIb/IIIa inhibitors and clopidogrel alone or in combination was associated with the reduction of all-cause mortality in the setting of primary PCI in comparison with aspirin alone. The benefit of antiplatelet treatment in the reduction of all-cause mortality was independent of the underlying clinical and angiographic risk factors. However, we also found that the use of GP IIb/IIIa inhibitors on top of 300 mg loading dose of clopidogrel did not further reduce mortality. This finding may have an important clinical impact, as current ESC guidelines for STEMI refer to the efficacy of abciximab administration on top of loading doses of clopidogrel as not elucidated.
